Oser Communications Group

Chain Drug Store Annual Meeting Apr 25 2015

Issue link: http://osercommunicationsgroup.uberflip.com/i/499803

Contents of this Issue


Page 0 of 31

An interview with Kon Ostaficiuk, President of Camber Pharmaceuticals. CDD: Tell our readers why Camber has grown so dramatically over the past sev- eral years. KO: It begins with a commitment by each individual in our company to never lose sight of the needs of our customers. From sales and pricing to cus- tomer service, everyone is pulling in the same direction. We know we have to earn our customers' business every day and in every way. So if it means developing a cus- tomized program for a particular partner, or staying late on a holiday weekend to make sure all our orders are An interview with Mike Coughlin, President and CEO, ScriptPro. CDD: How is the robot business doing in this changing healthcare environment? MC: Quite well. Automation is more important than ever to pharmacies. We have over 7,000 robots working in pharmacies around the world and the technology ScriptPro pioneered 20 years ago has kept up with the needs of the industry. Almost all of the robots we have ever built are still in service and we see no end of life for these machines. We are now bringing some of the older units back to the fac- tory for refurbishing and we send them back to the Under the direction of CEO, Andrew Burch, and a newly invigorated execu- tive team of experts in research and development, marketing and retail sales, SmartMouth is about to get a major charge of fresh, new energy and long- lasting lift! David Biernbaum, key adviser to Triumph Pharmaceuticals and industry marketing and retail sales specialist, explains that SmartMouth, currently sold boxed in two separate bottles with pumps, will re-launch in July 2015 with a "dual-bottle, single-pour delivery system with a patented dual pour spout." Until now, the patented two-solutions formula used by SmartMouth to deliver 12 hours of clean fresh breath per rinse, has Continued on Page 29 Continued on Page 25 Continued on Page 29 CAMBER'S IMPRESSIVE GROWTH TIED TO QUALITY, SERVICE, TEAMWORK SMARTMOUTH MOUTHWASH RE-LAUNCHES IN MID-SUMMER 2015 SCRIPTPRO BRINGS DEEP UNDERSTANDING TO MAKE PHARMACIES SUCCESSFUL O s e r C o m m u n i c a t i o n s G r o u p P a l m B e a c h S a t u r d a y, A p r i l 2 5 , 2 0 1 5 AN INDEPENDENT PUBLICATION NOT AFFILIATED WITH NACDS An interview with Diane Sullivan, V.P. Market Access and Patient Strategies, AstraZeneca. CDD: Tell us about AstraZeneca. DS: AstraZeneca is a global, innovation- driven biopharmaceutical business that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, ASTRAZENECA RETURNS TO NACDS AM By Dale Smith, Chairman and CEO, H. D. Smith Holding Company At H. D. Smith, great pride is taken in the offer- ings provided to improve the quality of health in this great country. Founded by my father in 1954, H. D. Smith has a rich history of wholesale distribution to pharmacies across the nation. Even in the company's infancy, we were flexible and created value for customers in a variety of ways. We've grown and evolved alongside our Roxane Laboratories Inc. (RLI) has grown into a successful differentiated generic pharmaceutical business with over $650 million in annual revenue. Its broad product portfolio is structured to meet the dynamic needs of the changing health- care marketplace and its customers. Operating as the research and devel- opment arm as well as the sales and mar- keting arm for Boehringer Ingelheim's generic pharmaceutical business, Roxane markets more than 75 medications in BETTER PATIENT HEALTH FROM COLLABORATION IN HEALTHCARE SYSTEM ROXANE LABORATORIES INC. STRUCTURED FOR HEALTHCARE NEEDS Continued on Page 25 Continued on Page 25 Continued on Page 22 Now, less is an option. GAVIS Pharmaceuticals is pleased to announce the introduction of GaviLyte™-H, the most recent addition to the GaviLyte line of products. This 2-liter volume PEG-3350 with bisacodyl tablet and salts provides an alternative pre- colonoscopy prep and is now available as a value-branded generic. GAVIS Pharmaceuticals remains committed to delivering valuable prod- ucts to the market that make a difference in people's lives. GaviLyte-H is part of GAVILYTE-H WITH BISACODYL TABELT BOWEL PREP KIT Continued on Page 29

Articles in this issue

view archives of Oser Communications Group - Chain Drug Store Annual Meeting Apr 25 2015